NX-5948
Highest phase reached
Phase 1
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Small molecule
- Drug name
- NX-5948
- Molecular weight
- 806.97
- Structure (SMILES)
- CN1CCN([C@@H]2CCCN(c3cnc(C(N)=O)c(Nc4ccc(C5CCN(CC6CCN(c7ccc(C(=O)N[C@H]8CCC(=O)NC8=O)nc7)CC6)CC5)cc4)n3)C2)C1=O
- bexobrutideg
- Bexobrutideg
- bexobrutideg [INN]
- BEXOBRUTIDEG [USAN]
- bexobrutideg inn
- bexobrutideg usan
- btk in 24
- BTK-IN-24
- nx 5948
- NX 5948 [WHO-DD]
- nx 5948 who dd
- Nx-5948
- NX-5948
- CAS registry numbers
- 2649400-34-8
- ChEMBL ID
- CHEMBL5558927
- InChIKey
- HPTPDBYCFHFWJG-CWTKIQHKSA-N
- PubChem compound IDs
- 156464216
- FDA ingredient codes (UNII)
- HVD6HGW6JD
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- bexobrutideg
- Type
- Synthetic organic
- Condition identifier
- EFO_0000095
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005952
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002571
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004948
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0017604
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018876
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018905
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018906
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018908
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0100280
- Highest recorded phase
- 1
- Hydrogen bond acceptors
- 12
- Hydrogen bond donors
- 4
- Polar surface area
- 202.33
- Calculated partition coefficient (ALogP)
- 2.68
- Calculated partition coefficient (XLogP)
- 2.6
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 11
- Heavy atoms
- 59
- Molecular formula
- C42H54N12O5
- Monoisotopic mass
- 806.43401287
- Natural product
- No
- Recorded assays
- 25
- Active assays
- 2
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (6)
- A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers
- A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948
- Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
In development for (2)
- B-cell chronic lymphocytic leukemia Phase 2
- Non-Hodgkin lymphoma Phase 1